Drug intelligence / Profile preview

TAM-02

Development stage: Preclinical
Lead developer: Mount Tam Biotechnologies
Modality: Small Molecules
Administration: Oral

Overview

TAM-02 is a polyketide compound developed by Mount Tam Biotechnologies under an exclusive worldwide license and collaboration agreement with the Buck Institute for Research on Aging. It is being developed as a second asset in a portfolio targeting autoimmune diseases, with a primary indication for multiple sclerosis. Its mechanism of action involves mTOR inhibition.

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on TAM-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAM-02.

Explore the full profile